Suchergebnisse - "Dudnik, Elizabeth"

PubPharm (7)

1

ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data

enthalten in: The oncologist | 2022

von Moskovitz, M. | Dudnik, E. | Shamai, S. | +13

2

Bevacizumab for stereotactic radiosurgery-induced radiation necrosis in patients with non-small cell lung cancer treated with immune check-point inhibitors

enthalten in: Journal of the neurological sciences | 2021

von Moore, A. | Yust-Katz, S. | Icht, O. | +8

3

Next-generation sequencing in thyroid cancers : do targetable alterations lead to a therapeutic advantage?: A multicenter experience

enthalten in: Medicine | 2021

von Moore, A. | Bar, Y. | Maurice-Dror, C. | +9

4

Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung

enthalten in: Journal for immunotherapy of cancer | 2021

von Dudnik, E. | Kareff, S. | Moskovitz, M. | +11

5

Effectiveness and safety of nivolumab in advanced non-small cell lung cancer : The real-life data

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2018

von Dudnik, E. | Moskovitz, M. | Daher, S. | +17

6

BRAF Mutant Lung Cancer : Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2018

von Dudnik, E. | Peled, N. | Nechushtan, H. | +17

CommentIn: J Thorac Oncol. 2018 Aug;13(8):1055-1057. - PMID 30056857

7

Biomarker-Driven Therapy in Metastatic Gastric and Esophageal Cancer : Real-Life Clinical Experience

enthalten in: Targeted oncology | 2018

von Purim, O. | Beny, A. | Inbar, M. | +21

1
[1]